Development of a New Therapy for the Treatment of Chronic Ulcerative Lesions Through Allogeneic Transplantation of a Subpopulation of Mesenchymal Stem Cells Derived from Human Umbilical Cords

The study explores a new therapy for chronic ulcerative skin lesions using allogeneic transplantation of a specific subpopulation of mesenchymal stem cells derived from human umbilical cords (CMMcu), termed mesenchymal-derived cells (CMD). These cells were selected based on their immunomodulatory and pro-regenerative profiles, showing high expression of biomarkers like HLA-G and VEGF-A. The CMDs demonstrated significant wound healing acceleration and improved tissue quality in murine models, with a controlled inflammatory response. Additionally, a preclinical equine model confirmed the safety and efficacy of the therapy, showing reduced healing times and improved tissue structure. These findings suggest that CMDs and equine mesenchymal cells (eqMC) have strong potential as regenerative medicine therapies for chronic skin lesions in both veterinary and human medicine.